Business Context and Reporting Period
This Form 8-K was filed by NanoVibronix, Inc. (trading symbol: NAOV) on August 30, 2023. The report details a material definitive agreement entered into on the same date regarding a private placement of equity securities. Note: The request metadata references "Envue Medical, Inc.," but the filing text explicitly identifies the registrant as NanoVibronix, Inc.
Key Financial Metrics and Transaction Details
- Net Proceeds: Approximately $4.3 million (after deducting placement agent fees, expenses, and estimated offering costs).
- Securities Issued:
- 180,000 shares of Common Stock.
- Pre-Funded Warrants to purchase up to 2,726,977 shares (exercise price: $0.0001).
- A-1 Warrants to purchase up to 2,906,977 shares (exercise price: $1.47; term: 5.5 years).
- A-2 Warrants to purchase up to 2,906,977 shares (exercise price: $1.47; term: 13 months).
- Purchase Price: $1.72 per Common Share plus accompanying warrants; $1.7199 per Pre-Funded Warrant plus accompanying warrants.
- Placement Agent Fees:
- Cash fee: 7.5% of aggregate gross proceeds.
- Management fee: 1.0% of aggregate gross proceeds.
- Non-accountable expense allowance: $50,000.
- Legal and out-of-pocket expenses: $100,000.
- Placement Agent Warrants: 218,023 shares at an exercise price of $2.15 (term: 5.5 years).
Material Changes and Use of Proceeds
The filing represents a significant capital raise event rather than a periodic financial performance report. Consequently, there are no comparative revenue, profit, or margin metrics provided in this document. The primary material change is the increase in outstanding equity and the influx of liquidity.
Intended Use of Proceeds: The Company plans to utilize the net proceeds for general corporate purposes, specifically:
- Funding development programs.
- Commercial planning and sales/marketing expenses.
- Potential strategic acquisitions.
- General and administrative expenses.
- Working capital.
Guidance, Risks, and Contingencies
Registration Rights: The Company entered into a Registration Rights Agreement requiring the filing of a registration statement with the SEC within 15 days of the agreement date. The Company must use best efforts to have the statement declared effective within 45 days (or 75 days in the event of a full SEC review).
Beneficial Ownership Limitations: Holders of Pre-Funded Warrants and Warrants are restricted from exercising if it would result in beneficial ownership exceeding 4.99% (or 9.99% at the holder's election) of outstanding shares. The limit can be increased to 9.99% with 61 days' prior notice.
Unregistered Sales: The securities were issued in reliance on exemptions from registration under Section 4(a)(2) of the Securities Act and Regulation D.
Investor Verification Checklist
- Verify the total gross proceeds raised to confirm the exact dilution impact on existing shareholders.
- Confirm the effective date of the registration statement filed for the resale of the securities.
- Review the Company's cash position prior to this transaction to assess runway extension.
- Monitor the exercise of Pre-Funded Warrants, which may convert to common stock at a nominal price, affecting share count.
- Check for any subsequent filings regarding the status of the "potential strategic acquisitions" mentioned in the use of proceeds.